Inhibition of autophagy in peripheral blood mononuclear cells by vaginal fluid from women with a malignant adnexal mass
暂无分享,去创建一个
T. Caputo | K. Holcomb | T. Orfanelli | S. Witkin | T. Kanninen | G. Sisti | D. Gupta | G. Doulaveris | Jiyeon Jeong
[1] E. Diamandis,et al. Effectiveness of the Risk of Malignancy Index and the Risk of Ovarian Malignancy Algorithm in a Cohort of Women With Ovarian Cancer: Does Histotype and Stage Matter? , 2015, International Journal of Gynecologic Cancer.
[2] K. Holcomb,et al. Involvement of autophagy in cervical, endometrial and ovarian cancer , 2014, International journal of cancer.
[3] Sang Gyun Kim,et al. Rapamycin: one drug, many effects. , 2014, Cell metabolism.
[4] S. Witkin,et al. Inhibition of Autophagy by Sera From Pregnant Women , 2013, Reproductive Sciences.
[5] H. Stenmark,et al. p62 at the interface of autophagy, oxidative stress signaling, and cancer. , 2012, Antioxidants & redox signaling.
[6] O. Camara,et al. Preoperative Multimodal Strategies for Risk Assessment of Adnexal Masses: Analysis of 1362 Cases in a Gynecologic Cancer Center , 2011, International Journal of Gynecologic Cancer.
[7] M. Komatsu,et al. Selective degradation of p62 by autophagy , 2010, Seminars in Immunopathology.
[8] Steven J Skates,et al. Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. , 2010, American journal of obstetrics and gynecology.
[9] B. Davidson,et al. Mammalian target of rapamycin is a biomarker of poor survival in metastatic serous ovarian carcinoma. , 2010, Human pathology.
[10] Mihee M. Kim,et al. The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1 , 2010, Nature Cell Biology.
[11] Zhen Lu,et al. The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells. , 2008, The Journal of clinical investigation.
[12] R. Deng,et al. Decreased expression of autophagy-related proteins in malignant epithelial ovarian cancer , 2008, Autophagy.
[13] F. Bredin,et al. Use of sirolimus (rapamycin) to treat refractory Crohn’s disease , 2008, Gut.
[14] J. Flores,et al. The signaling adaptor p62 is an important NF-kappaB mediator in tumorigenesis. , 2008, Cancer cell.
[15] D. Klionsky,et al. Autophagosome formation: core machinery and adaptations , 2007, Nature Cell Biology.
[16] G. Bjørkøy,et al. p62/SQSTM1 Binds Directly to Atg8/LC3 to Facilitate Degradation of Ubiquitinated Protein Aggregates by Autophagy* , 2007, Journal of Biological Chemistry.
[17] T. Hagemann,et al. The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells. , 2007, Cancer research.
[18] B. Rosen,et al. Who should operate on patients with ovarian cancer? An evidence-based review. , 2005, Gynecologic oncology.
[19] S. Emr,et al. Autophagy as a regulated pathway of cellular degradation. , 2000, Science.
[20] E J Pavlik,et al. A morphology index based on sonographic findings in ovarian cancer. , 1993, Gynecologic oncology.
[21] D. Oram,et al. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer , 1991, British journal of obstetrics and gynaecology.
[22] R. Bast,et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. , 1983, The New England journal of medicine.
[23] S. Ryter,et al. Autophagy in human health and disease. , 2013, The New England journal of medicine.
[24] Richard G. Moore,et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. , 2009, Gynecologic oncology.
[25] R. Bast,et al. The CA 125 tumour-associated antigen: a review of the literature. , 1989, Human reproduction.